DAPA-HF One Year on: What Have You Missed?

Published: 31 July 2020

  • Views:

    Views Icon 177

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focused upon analysing the DAPA-HF SGLT2 randomised clinical trial and subsequent sub-analysis data that been published over the last 12 months.

Agenda

  • Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF - John McMurray (University of Glasgow, Glasgow, UK)
  • Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF - Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL)
  • DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF- Scott Solomon (Brigham & Women’s Hospital, Boston, US)
  • Impact of Dapagliflozin Treatment on KCCQ - Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US)
  • Dapagliflozin and Diuretic Use in Patients With HFrEF - Alice Jackson (University of Glasgow, Glasgow, UK)

More from this programme

Part 1

Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF

1 session
Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF Watch now

Part 2

Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF

1 session
Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF Watch now

Part 3

DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF

1 session
DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF Watch now

Part 4

Impact of Dapagliflozin Treatment on KCCQ

1 session
Impact of Dapagliflozin Treatment on KCCQ Watch now

Part 5

Dapagliflozin and Diuretic Use in Patients With HFrEF

1 session
Dapagliflozin and Diuretic Use in Patients With HfrEF Watch now

Faculty Biographies

Alice Jackson

Alice Jackson

View full profile